OMER

10.31

0.68% 0.07

Dopo l'orario di chiusura: 10.27 -0.04 -0.39%

Omeros Corporation (OMER)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$10.24

Aprire:

$10.08

Volume 24 ore:

2.43M

Relative Volume:

2.80

Capitalizzazione di mercato:

$597.46M

Reddito:

Utile/perdita netta:

$-117.81M

Rapporto P/E:

16.11

EPS:

0.64

Flusso di cassa netto:

$74.30M

1 W Prestazione:

+35.12%

1M Prestazione:

+70.98%

6M Prestazione:

+160.68%

1 anno Prestazione:

+244.82%

Intervallo 1D:

$10.08

$12.83

Intervallo di 1 settimana:

$7.20

$13.60

Portata 52W:

$2.612

$13.60

Omeros Corporation Stock (OMER) Company Profile

Nome

Omeros Corporation

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

206-676-5000

Indirizzo

201 ELLIOTT AVENUE WEST, SEATTLE, WA

Dipendente

198

Cinguettio

@OmerosCorp

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

OMER's Discussions on Twitter

Confronta OMER con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OMER Omeros Corporation	10.31	597.46M	0	-117.81M	74.30M	-1.88
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-14	Iniziato	Rodman & Renshaw	Buy
2022-12-08	Downgrade	UBS	Buy → Neutral
2022-11-08	Downgrade	BofA Securities	Neutral → Underperform
2022-06-08	Downgrade	BofA Securities	Buy → Neutral
2021-10-08	Downgrade	JP Morgan	Neutral → Underweight
2021-10-01	Downgrade	Maxim Group	Buy → Hold
2021-10-01	Downgrade	Wedbush	Neutral → Underperform
2021-09-27	Iniziato	JP Morgan	Neutral
2021-02-01	Iniziato	UBS	Buy
2020-10-20	Iniziato	BofA Securities	Buy
2020-08-21	Reiterato	H.C. Wainwright	Buy
2020-08-14	Reiterato	Maxim Group	Buy
2019-05-06	Iniziato	Cantor Fitzgerald	Overweight
2018-07-12	Iniziato	Seaport Global Securities	Buy
2018-03-23	Downgrade	Wedbush	Outperform → Neutral
2018-03-05	Downgrade	Needham	Buy → Hold
2017-11-08	Iniziato	H.C. Wainwright	Buy
2017-05-11	Downgrade	Cantor Fitzgerald	Buy → Neutral
2017-03-17	Reiterato	Maxim Group	Buy
2017-03-17	Reiterato	Needham	Buy
2016-11-16	Reiterato	Wedbush	Outperform
2016-11-10	Reiterato	Needham	Buy
2016-08-10	Reiterato	Maxim Group	Buy
2016-06-03	Iniziato	Cantor Fitzgerald	Buy
2016-03-02	Reiterato	Needham	Buy
2016-02-29	Reiterato	Wedbush	Outperform
2015-11-11	Reiterato	Needham	Buy
2015-08-18	Reiterato	WBB Securities	Strong Buy
2015-08-10	Iniziato	ROTH Capital	Buy

Mostra tutto

Omeros Corporation Borsa (OMER) Ultime notizie

Dec 21, 2024

Wellington Management Group LLP Invests $305,000 in Omeros Co. (NASDAQ:OMER) - MarketBeat

Dec 21, 2024

Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER) - Defense World

Dec 21, 2024

Omeros Corporation Announces Positive Results for Narsoplimab in Treating Thrombotic MicroangiopathyOn December 19, 2024, Omeros Corporation (NASDAQ: OMER) revealed the outcomes of a primary statistical analysis involving narsoplimab, the comp - Defense World

Dec 21, 2024

Dec 20, 2024

Omeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat

Dec 20, 2024

BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER) - Defense World

Dec 20, 2024

Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN

Dec 19, 2024

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Benzinga

Dec 19, 2024

Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat

Dec 19, 2024

Omeros Stock Gains 52% On Successful Trial Results - MarketWatch

Dec 19, 2024

Omeros antibody improves overall survival by 68% in rare condition, new analysis finds - Fierce Biotech

Dec 19, 2024

Omeros stock soars to 52-week high, hits $12.65 - Investing.com

Dec 19, 2024

Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges - Yahoo Finance

Dec 19, 2024

Omeros stock surges on positive survival data for narsoplimab - Investing.com

Dec 19, 2024

Omeros stock jumps after trial outcome (OMER:NASDAQ) - Seeking Alpha

Dec 19, 2024

Omeros reports survival benefit with narsoplimab in TA-TMA - Investing.com

Dec 19, 2024

Omeros announces narsoplimab trial meets primary endpoint - TipRanks

Dec 19, 2024

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA - Business Wire

Dec 19, 2024

Dec 18, 2024

Omeros (STU:3O8) Operating Income : €-159.24 Mil (TTM As of Sep. 2024) - GuruFocus.com

Dec 18, 2024

Omeros (STU:3O8) GF Score : 50/100 (As of Dec. 18, 2024) - GuruFocus.com

Dec 18, 2024

Dec 14, 2024

Omeros Co. (NASDAQ:OMER) Short Interest Down 16.9% in November - MarketBeat

Dec 14, 2024

Dec 12, 2024

Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates - Seeking Alpha

Dec 12, 2024

Dec 11, 2024